SiliconInvestor
     Advanced Search   [ sign in ]

sponsor
Sponsor

 Biotech / Medical : CUBIST PHARMACEUTICALS (CBST)

 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  
To: kenhott who wrote (248)4/8/2011 1:30:44 PM
From: IRWIN JAMES FRANKELRead Replies (1) of 252
 
I would think SG&A will be lower as legal patent defense is over and mitigated by the OPTR deal revenue.

Still a lot left that could benefit a buyer.

Are there any other generic challengers to the Cubicin patents?

IF NOT, then CBST has a couple of years of duopoly after Teva launches. That is worth quite a bit if as management suggests Cubicin is heading for $1B in sales.

ij
Report TOU ViolationShare This Post
 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQ
Copyright © 1995-2013 Knight Sac Media. All rights reserved.